Search results
US pharma giant Cencora says Americans' health information stolen in data breach
TechCrunch· 3 days agoU.S. pharmaceutical giant Cencora says it is notifying affected individuals that their personal and...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
WJET - WFXP Erie· 2 days ago...atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KOIN News 6 Portland· 2 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
UBS Group AG Has $167.76 Million Stock Holdings in Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 6 days agoUBS Group AG trimmed its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 9.9% during the fourth quarter, according to its most recent disclosure with the Securities ...
Novartis to seek approvals in two rare kidney diseases after positive Phase 3 trials
Endpoints News· 2 days agoNovartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the...
Level Four Advisory Services LLC Cuts Stock Position in Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 7 days agoLevel Four Advisory Services LLC trimmed its holdings in shares of Novartis AG (NYSE:NVS – Free Report) by 5.9% during the 4th quarter, according to the company in its most ...
Novartis Patient Information Leaked in Third-Party Data Breach at Lash Group | JD Supra
JD Supra· 3 days agoIn this notice, Lash Group explains that the incident resulted in an unauthorized party being able to access sensitive information belonging to patients enrolled in “patient support programs ...
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks via Yahoo Finance· 6 days agoSo, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow...
Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signal
FierceBiotech· 6 days agoEli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to...
A corner of the cancer therapy market is heating up—Here are the names investors need to know
CNBC· 3 days agoThere's been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted ...